Servier – Servier’s commitment to immuno-inflammation

IMMUNO-INFLAMMATION

Satisfying a major medical need

Already involved in Sjögren’s syndrome, we also direct our research and development efforts on pathologies with considerable medical need, where the mechanisms and symptoms make it possible for proof-of-concept studies to demonstrate efficacy early.

We endeavor to develop new treatment options to respond to this major medical need that is affecting more and more people around the world.

Correcting dysfunctional immune responses

Autoimmune diseases are characterized by an inappropriate immune system response that turns against the patient’s own tissues or organs. They affect approximately 5 to 8% of the world’s population¹.

They are caused by multiple factors, which differ from one patient to the next, despite them all suffering from the same disease. It has become a challenge for the pharmaceutical industry to make innovative therapeutic solutions available to patients.

At Servier, we develop targeted therapies to correct the inappropriate immune response through different approaches such as:

targeting a protein that plays a role in the pathology, such as the interleukin-7 receptor in Sjögren’s syndrome.
targeting various adaptive immune system mechanisms, which could stop the production of auto-antibodies that drive disease.

Developing targeted therapeutic solutions

We focus our research on therapeutic solutions that offer a targeted approach on the pathological mechanisms that cause autoimmune diseases, especially monoclonal antibodies, which are therapeutic antibodies that have been specifically selected and engineered to bind and modify the activity of targets known to be involved in the disease.

As part of the recent evolution of precision medicine approaches in drug discovery and development, antisense oligonucleotides (ASOs) have shown promise to revolutionize the treatment of particularly rare and genetically driven or inherited disease.

Read the insight

Learn more about our immuno-inflammation development projects

See the pipeline

For patients

Understanding Sjögren’s syndrome, an auto-immune disease

Sjögren’s syndrome is the second most common autoimmune disease after rheumatoid arthritis. It is caused when the immune system does not function as it should, and most often leads to a dry mouth and dry eyes, along with joint pain and prolonged fatigue. In a third of cases it also affects other major organs such as the lungs, kidneys and the peripheral nervous system. There is currently no cure for the disease itself, and treatment focuses on relieving the symptoms.

Read the insight